Purpose Approximately 50% of glioblastomas (GBMs) are characterized by overexpression
of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In …

Erlotinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is active in
glioblastoma. We evaluated erlotinib efficacy in patients with first-relapse glioblastoma and …

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase
inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the …

Targeting the epidermal growth factor receptor (EGFR) may be effective in a subset of
glioblastoma patients. This phase II study assessed the clinical activity of erlotinib plus …

Background Inhibition of epidermal growth factor receptor (EGFR) and the mechanistic
target of rapamycin (mTOR) may have synergistic antitumor effects in high-grade glioma …

Patients with (a) recurrent malignant glioma (MG): glioblastoma (GBM) or recurrent
anaplastic glioma (AG), and (b) nonprogressive (NP) GBM following radiation therapy (RT) …

Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR)
signaling are established contributors to malignant glioma (MG) biology. We, therefore …

Background The signal transduction pathways of epidermal growth factor receptor and Ras
are both important in the growth of glioblastoma multiforme (GBM). We hypothesized that …

The purpose of this study was to define the maximum tolerated dose of erlotinib and
characterize its pharmaco-kinetics and safety profile, alone and with temozolomide, with and …

Purpose Epidermal growth factor receptor (EGFR) amplification in glioblastoma multiforme
(GBM) is a common occurrence and is associated with treatment resistance. Erlotinib, a …